New Zealand markets closed

Tiziana Life Sciences PLC (TLSA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.7895-0.0605 (-7.12%)
At close: 04:00PM EST
0.8240 +0.03 (+4.37%)
After hours: 04:19PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.8500
Open0.8245
Bid0.0000 x 800
Ask0.0000 x 800
Day's range0.7736 - 0.8500
52-week range0.6600 - 4.9900
Volume96,999
Avg. volume140,983
Market cap76.823M
Beta (5Y monthly)-0.02
PE ratio (TTM)N/A
EPS (TTM)-0.2200
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.25
  • GlobeNewswire

    Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference

    NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer (NSCLC) and transformational drug delivery technologies to enable alternative routes of immunotherapy, today announced its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a virtual fireside chat at the B.Riley Securitie

  • GlobeNewswire

    Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million

    NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company’s management to implement a stock repurchase program for up to $5 million of the Company’s common shares at any time. The term of the board authorization is until December 31, 2022. The repurchase program may be suspended or discontinued at any time and will be funded using the Company’s working capital. Executive Chairman Gabriele Cerrone c

  • GlobeNewswire

    Tiziana Life Sciences Announces Death of Director

    NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that Dr. Thomas Adams passed away on January 9, 2022. He served as a member of Tiziana Life Science’s Board of Directors since February 2021. Dr. Kunwar Shailubhai, the Company's CEO, commented, "It is with great sadness that we announce the passing of Dr. Tom Adams. He was a highly valued Di